Thrive Genetics, a company focusing on innovative solutions for addiction risk management with the goal of transforming addiction prevention and treatment through the integration of cutting-edge genomics and epidemiology, has signed an exclusive license with Rutgers, The State University of New Jersey.
Thrive Genetics will be offering for the first time Thrive CARES (Comprehensive Addiction Risk Evaluation System), which is based on over two decades of research funded by the National Institutes of Health and led by Thrive Genetics Co-Founder and Chief Scientific Officer Dr. Danielle Dick, who also serves as Director of the Rutgers Addiction Research Center.
Thrive CARES represents a paradigm shift, leveraging advanced genomic markers and behavioral/environmental analysis to help individuals understand their personalized risk profiles, prevent problems before they start, and assist with treatment management and recovery support.
“This agreement is a monumental step towards our ultimate goal of empowering individuals with personalized addiction risk insights,” said CEO of Thrive Genetics, James Piacentino. “Combining our innovative technology with Rutgers’ esteemed research capabilities allows us to significantly advance addiction management strategies by providing tailored care plans and refining data-driven decision-making for at-risk individuals.”
“We have made tremendous advances in understanding genetic contributions to addiction in recent years, along with the behavioral and environmental factors that put individuals at greatest risk of developing problems. At the Rutgers Addiction Research Center, we are committed to finding innovative ways to bring the latest scientific discoveries to the public, so that everyone can benefit. The launch of Thrive Genetics is an example of that commitment”, said Dr. Dick.
In addition to benefiting individual patients, this agreement’s implications extend to veterans, corporate wellness programs, and even sectors like responsible gaming, where Thrive Genetics’ solutions are being recognized for their potential in proactive health interventions.
“Thrive Genetics is working to apply genetic and environmental research into why some individuals are at higher risk of addiction, transforming strategies to manage that risk better and improve people’s lives,” said Vince Smeraglia, executive director of New Ventures at Rutgers Office for Research, which negotiated the license with the company. “The research was conducted at our Rutgers Addiction Research Center, the largest addiction research center in the world, and the company’s leadership is working closely with that center to develop it further.”
“The Office for Research congratulates Dr. Dick and the Thrive Genetics team on the launch of their company, which is based on their proprietary Thrive CARES innovation that was developed at Rutgers,” said Michael E. Zwick, senior vice president for Research. “Rutgers researchers look for solutions to the world’s problems, and Thrive Genetics is an example of how the work being done here at Rutgers translates to real-world impact.”
Story courtesy of Thrive Genetics